Here is an English language translation from CGPT5 of the company’s china website:
Here’s an English-language summary of the main content on the website of Platinum Life Excellence Biotech (Beijing) Co., Ltd. (Chinese: 铂生卓越生物科技（北京）有限公司). The site covers several sections: “About Us”, “Products & Services”, “Company News”, and “Contact / Careers”.
⸻
About Us
• The company was founded in 2010 and operates in the stem-cell biotech space. 
• Its lead product, Amimestrocel Injection (Chinese: 艾米迈托赛注射液), was conditionally approved by China’s regulator on January 2, 2025, making it the first approved stem-cell therapy in China. 
• The company claims to have built a large-scale production platform: a three-dimensional degradable microcarrier suspension culture system (automated, continuous, fully closed) for stem-cell drug manufacture, and a full lifecycle information-traceability system that tracks stem-cell products from donor to patient. 
• Their stated mission: “Born of love, acting by faith – to make stem-cell drugs that ordinary people can access and afford.” (rough translation of the Chinese) 
• Their vision: Become a first-class enterprise in the field of stem-cells. 
• Milestones listed:
• 2010: Company founded. 
• 2018: Submitted stem-cell clinical research report to the Chinese regulator (CDE) and got approval to begin Phase II clinical trials. 
• 2020-22: Initiated and completed a randomized double-blind multicenter Phase II trial. 
• 2023: Initiated key Phase III trial. 
• 2024: Completed Phase III trial; obtained China’s first stem-cell drug manufacturing licence. 
• 2025: Obtained China’s first “stem-cell new drug certificate” (i.e., approval for listing) for Amimestrocel Injection. 
⸻
Products & Services
• Their flagship product is Amimestrocel Injection. The website describes its indication: for patients (age 14 and above) with acute graft-versus-host disease (aGVHD) following hematopoietic stem-cell transplant, who are steroid-refractory (i.e., failed standard first-line treatment). 
• The mechanism description: The product uses human umbilical-cord-derived mesenchymal stem cells (hUC-MSC). Through both cell-to-cell contact and paracrine signalling (e.g., secreting prostaglandin E2 (PGE2), IL-6, indoleamine-2,3-dioxygenase (IDO)), it boosts regulatory T cells (Treg) and Th2 cells (anti-inflammatory) while suppressing Th1 and B cells (pro-inflammatory). The effect: reduced inflammation, tissue repair, lowered incidence and severity of acute GVHD, and opens up new therapeutic options in immune-related diseases. 
• There’s a customer service / pharmacovigilance hotline and email for drug safety/adverse-reaction reporting: Phone: 400-819-0099; Email: bszypv@platinumlife.cn and boshengzhuoyue@platinumlife.cn. 
⸻
Company News (“Dynamics”)
• Key news items include:
• On January 2, 2025: The product Amimestrocel Injection was conditionally approved by the regulator (National Medical Products Administration, NMPA) for listing. 
• June 28, 2024: Their new-drug application (NDA) for Amimestrocel Injection became the first stem-cell new-drug application in China to be accepted and placed on the “priority review” list (acceptance number: CXSS2400062). 
• May 31, 2024: The company received China’s first stem-cell drug manufacturing licence. 
• June 17, 2025: They published their corporate green performance (environmental) evaluation materials. 
⸻
Contact & Address
• Company name: Platinum Life Excellence Biotech (Beijing) Co., Ltd. (铂生卓越生物科技（北京）有限公司) 
• Address: Building 7, No. 8 Ruihe West 2nd Road, Beijing Economic & Technological Development Area (Beijing Economic-Technological Development Area), Beijing, China. 
• Customer service line: 400-819-0099. 
• Company email: boshengzhuoyue@platinumlife.cn 
• Business registration: ICP licence number “京ICP备2022016208号”. 
⸻
Summary of Key Takeaways
• This company is a Chinese stem-cell biotech that claims to be the first in China to bring a stem-cell drug (Amimestrocel Injection) to market (for steroid-refractory aGVHD).
• They have built infrastructure for large-scale stem-cell drug manufacture (3D microcarrier suspension culture, automated/closed lines, traceability systems).
• They emphasise accessibility (“drugs for ordinary people to use and afford”) and aim to become a leading stem-cell enterprise.
• They maintain pharmacovigilance and customer-service infrastructure (hotline + email for adverse-reaction reporting).
• They are headquartered in Beijing, with full contact details listed.
⸻